Chuck Broes draws on over forty years of business acumen to offer a perspective on business philosophies and tactics for the next decade. This piece is part 5 of a series.
Quantum Immunologics’ Chuck Broes places high importance on knowing the minds of his executive management team. When a CEO like Chuck Broes understands the goals and motivations of his managers, he truly has his finger on the company’s pulse. Chuck Broes approaches key management hires with his sights tuned to the relationship between a candidate’s talents and appropriate compensation. A key management hire by Chuck Broes is meant to suit the individual as much as it serves the company. A necessary ingredient for success, believes Chuck Broes, is that each hire must contribute to one or more goals of the corporation.
There are many tools at Chuck Broes’ disposal when it comes to recruiting senior management. Recognizing that remuneration usually includes the promise of long-term benefit potential that includes stock options and warrants, Chuck Broes acknowledges that such upsides are something that most candidates expect these days. “The key,” says Chuck Broes, “is to promote the long-term value associated with public equities and tie that to team performance.” In Chuck Broes’ experience, when a talented senior manager joins a small company, the notion of profitability promptly becomes a discussion of equity. Chuck Broes is and always will be a strong advocate for long-term benefits and equity for key management.
In like manner, Chuck Broes keeps a “long game” strategy in mind when he and his executive team at Quantum Immunologics are courting stakeholders. Keeping a long-term plan bright in his mind, Chuck Broes helps management make better decisions and embrace a team attitude. Chuck Broes points out that if all parties can benefit –stakeholders, management and the company as a whole – then everyone will come to appreciate the contributions of their counterparts. This is the secret to true success, notes Chuck Broes. Over the decades, Chuck Broes has honed this business philosophy and seen it reap great rewards. In the modern global business world, change comes faster than ever and this philosophy more critical today than it ever was in the past.
About Chuck Broes
Chuck Broes is a business and healthcare visionary whose career spans over 45 years in domestic and foreign markets. In the past, Chuck Broes has specialized in the areas of incubation, start-ups, mergers and acquisitions, corporate turn-arounds and roll-ups. Chuck Broes has served in various executive roles including Chief Executive Officer, Chief Financial Officer and Chief Operating Officer.
Chuck Broes began his unique career with Health Industries (Jack LaLanne European Health Spas) from its founding to becoming a national chain of over one hundred locations, then going public and later being sold to a Fortune 500 company. This positioned Chuck Broes to serve in key leadership roles within the healthcare and pharmaceutical industries working with regulatory issues involving the FDA, ISO and CE marking and EDI. Chuck Broes was involved intimately as part of the senior management team at Wellmark Corporation, a pioneer company in healthcare clearinghouse services and ANSI X12 standards, which became a subsidiary of Primark Corporation, a NYSE Company.
Later, Chuck Broes founded EliteCorp International, Inc. and served as its Chief Executive Officer. In that capacity Chuck Broes’ business experience has included the facilitation of public companies, acquisitions, mergers, strategic alliances, IPOs and turnarounds. Associated projects for Chuck Broes have ranged from concept to development and production, including the integration of national data communication networks, facilities management, and healthcare system technologies.
Chuck Broes has served as a member of the Ethics Committee of the Moffitt Cancer Center in Tampa, Florida for fifteen years. In 2008, Chuck Broes turned his full attention to Quantum Immunologics, Inc., which he helped found and where he currently serves as CEO. Chuck Broes leads Quantum Immunologics in the pursuit of the research, development and implementation of new immunotherapy protocols for the treatment of cancer. Chuck Broes has initiated clinical trials that are currently underway and new patents have been filed providing the company with a pipeline for ongoing improvements in cancer treatment.
According to Chuck Broes, Quantum Immunologics was formed for the sole purpose of developing, implementing and distributing new advanced levels of proprietary therapeutic treatments and diagnostic tools. Chuck Broes presents Quantum Immunologics’ mission as fostering the development and support for these and other technologies that are complementary to its current portfolio of patented intellectual properties that are focused on immune diseases and disorders.
To contact Chuck Broes or for more information about Quantum Immunologics please visit: www.quantumimmunologics.com or call 866-213-4594.